Pipeline

Our current pipeline

Science sourced worldwide

LianBio collaborates with world class partners, selecting programs with strong scientific basis and clinical data resulting in a broad and validated late-stage pipeline with first-in-class profile as well as other high potential candidates

Global Clinical Trials Status

Expected China Clinical Trials Status Upon Initiation

Cardiorenal

Pre-clinical

Phase 1/1B

Phase 2

Phase 3

Mavacamten

Obstructive Hypertrophic Cardiomyopathy (oHCM)

Non-obstructive Hypertrophic Cardiomyopathy (nHCM)

Precision Diastolic Disease (HFpEF)

Oncology

Infigratinib (BGJ398)

First-line Cholangiocarcinoma (1LCCA)

Second-line Cholangiocarcinoma (2LCCA)*

Urothelial Carcinoma – Adjuvant*

Gastric Cancer

Other FGFR-driven Tumors

*LianBio will pursue approval in ex-China LianBio Territories via CPP (i.e. clinical trial waivers with regulatory submission post US FDA approval).

BBP-398

SHP2 Inhibitor for RTK Cancers